| Trial ID: | L3812 |
| Source ID: | NCT03758144
|
| Associated Drug: |
Rifaximin 200 Mg
|
| Title: |
Rifaximin Improves Gut Dysbiosis in Insulin Resistance and Type 2 Diabetes
|
| Acronym: |
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type2 Diabetes
|
| Interventions: |
DRUG: Rifaximin 200 MG
|
| Outcome Measures: |
Primary: change in glycemic control, Fasting blood sugar, post-prandial blood sugar (mg/dl), 3 months | Secondary: Gastrointestinal symptom questionnaire, symptomatic improvement in Dyspepsia, distension, abdominal pain, 1 month | Other: change in weight, Weight loss in kilograms, 6 months
|
| Sponsor/Collaborators: |
Sponsor: Zagazig University
|
| Gender: |
ALL
|
| Age: |
ADULT
|
| Phases: |
|
| Enrollment: |
80
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2018-11-01
|
| Completion Date: |
2019-07-01
|
| Results First Posted: |
|
| Last Update Posted: |
2018-11-29
|
| Locations: |
Zagazig University, Zagazig, Sharkia, 44519, Egypt
|
| URL: |
https://clinicaltrials.gov/show/NCT03758144
|
